Related Experiment Videos
[Immunologic tests in the prognosis of solid malignant tumors]
La Semaine Des Hopitaux : Organe Fonde Par L'Association D'Enseignement Medical Des Hopitaux De Paris
|November 8, 1978
Summary
Immunological tests before cancer treatment can predict patient survival. Abnormal test results indicate a poorer prognosis, regardless of tumor spread, aiding treatment decisions.
Area of Science:
- Oncology
- Immunology
Context:
- Solid malignant tumors represent a significant global health challenge.
- Accurate prognostic indicators are crucial for effective cancer management.
- Evaluating the role of immunological markers in predicting patient outcomes.
Purpose:
- To investigate the correlation between pre-treatment immunological findings and patient survival rates.
- To assess the prognostic value of immunological test variations post-treatment.
- To determine if immunological status can predict survival independently of tumor stage.
Summary:
- Survival at 6, 12, and 24 months was analyzed in 600 solid tumor patients based on pre-treatment and post-treatment immunological tests.
- Prognosis worsens proportionally with the degree of change in immunological tests.
- Survival rates varied significantly: normal tests yielded higher survival (87% for localized tumors) compared to abnormal tests (11% for localized tumors with two abnormal test groups).
- Even with widespread metastases, normal immunological tests offered a better prognosis (24%) than localized tumors with disturbed tests (11%).
Impact:
- Pre-treatment immunological tests are valuable prognostic indicators, independent of tumor extension.
- These findings can significantly inform clinical decisions regarding cancer treatment strategies.
- Highlights the importance of integrating immunological assessments into routine cancer patient evaluation.